Concord Wealth Partners Exact Sciences Corp Transaction History
Concord Wealth Partners
- $548 Million
- Q1 2024
A detailed history of Concord Wealth Partners transactions in Exact Sciences Corp stock. As of the latest transaction made, Concord Wealth Partners holds 129 shares of EXAS stock, worth $5,568. This represents 0.0% of its overall portfolio holdings.
Number of Shares
129
Previous 129
-0.0%
Holding current value
$5,568
Previous $9,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EXAS
# of Institutions
699Shares Held
160MCall Options Held
5.84MPut Options Held
2.58M-
Vanguard Group Inc Valley Forge, PA17.7MShares$766 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA13MShares$562 Million0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY12.4MShares$535 Million0.08% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$491 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$461 Million0.13% of portfolio
About EXACT SCIENCES CORP
- Ticker EXAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 176,960,000
- Market Cap $7.64B
- Description
- Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...